Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - Raymond James lowered its price target on Hancock Whitney (NASDAQ:HWC) to $72.00 from $73.00 on Wednesday, while maintaining a Strong Buy rating following the bank’s third-quarter 2025 results. The bank, currently trading at $62.53 and commanding a market capitalization of $5.3 billion, sits near its 52-week high of $64.66.
The bank’s Q3 performance exceeded Raymond James’ forecasts and consensus estimates, showing fee income momentum, expense control, benign credit trends, ongoing capital return, and robust profitability. With a P/E ratio of 11.56 and a notable track record of maintaining dividend payments for 38 consecutive years, Hancock Whitney demonstrates strong financial fundamentals. Despite these positive factors, Raymond James reduced its out-year earnings per share estimates.
Hancock Whitney lowered its second-half 2025 loan growth guidance from mid-single to low-single digits due to ongoing loan paydowns. The bank’s net interest margin and net interest income fell short of forecasts, while non-interest-bearing deposits deteriorated. According to InvestingPro, the company maintains a GOOD financial health score, with particularly strong marks in profit and price momentum metrics.
The bank reiterated its full-year outlook but reduced its pre-provision net revenue growth guidance from 6-7% to 5-6%. Raymond James noted that a significant rebound in deposits during Q4 2025 would be needed for Hancock Whitney to meet the low end of its full-year net interest income and pre-provision net revenue guidance ranges.
Raymond James cited Hancock Whitney’s above-peer profitability, ongoing capital deployment, fee momentum, and benign credit metrics as positive factors, despite the stock’s discounted valuation compared to peers.
In other recent news, Hancock Whitney Corporation announced its third-quarter 2025 earnings, reporting an adjusted earnings per share (EPS) of $1.49, which exceeded the forecasted $1.43. Despite this positive EPS result, the company’s revenue slightly missed expectations, totaling $385 million compared to the projected $391.32 million. This discrepancy highlights a mixed financial performance for the quarter. Analysts had anticipated different outcomes, but the company’s strategic initiatives may have contributed to the positive investor sentiment. No significant mergers or acquisitions were reported in this period. Additionally, there were no analyst upgrades or downgrades mentioned in the recent developments. Investors and stakeholders are likely watching these metrics closely as they consider future decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.